Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

BHVN vs MESO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

BHVN Captures Overall Composite Edge (42.1 HOLD vs 35.5 SELL), While MESO Leads 3–2 on Growth & Valuation Pillars

BHVN Overall Winner 6-Pillar Tally: BHVN 2 – 3 MESO (1 Tie) Matrix Metrics: BHVN 5 – 3 MESO

As of Nov 16, 2026, Biohaven Ltd. (BHVN) captures the overall head-to-head institutional edge over Mesoblast Limited (MESO) on higher Unified Composite conviction (42.1/100 HOLD vs. 35.5/100 SELL) after splitting the core matrix 5–3 (led by Profitability & Quality, Options & Positioning), while MESO wins 3–2 across the 6-pillar growth and valuation breakdown. BHVN trades at $13.90 (N/M Forward P/E, 0.0% operating margin) versus MESO at $12.47 (N/M Forward P/E, -42.6% operating margin).

  • Growth vs. Quality Trade-Off: BHVN earns the overall head-to-head edge with a stronger Unified Composite Score (42.1/100 HOLD vs. MESO 35.5/100 SELL) and 1.41β · 111% Vol risk profile, whereas MESO leads top-line expansion (+390.7% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: BHVN is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 48.4); meanwhile MESO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 38.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About BHVN vs MESO
BHVN NYSE Head-to-Head Winner
Biohaven Ltd.
Pharmaceutical Preparations
$13.90
+0.62% 1D
Market Cap $2.1B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.41β · 111% Vol
Unified Composite Score
42.1 / 100 HOLD
Tech 15.0 Fund 42.0 Flow 68.0 Mom 50.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -0.9%) with fading momentum, RSI 48
RSI-14: 48.4 · SMA20: $14.55 · SMA50: $13.48
MESO NASDAQ
Mesoblast Limited American Depositary Shares
Biological Products, (No Diagnostic Substances)
$12.47
-6.03% 1D
Market Cap $1.7B
TTM Revenue $120M
Forward P/E N/M
Beta / 30D Vol 1.18β · 78% Vol
Unified Composite Score
35.5 / 100 SELL
Tech 25.0 Fund 40.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -8.5%), weak momentum, RSI 38
RSI-14: 38.3 · SMA20: $13.64 · SMA50: $14.22

6-Pillar Scorecard Institutional Category Breakdown (BHVN 2 – 3 MESO)

Columns: Metric · BHVN · MESO
1. Valuation Multiples MESO
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M 14.1x
2. Growth & Scale MESO
Revenue Growth (YoY) +0.0% +390.7%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $120M
Market Cap $2.1B $1.7B
3. Profitability & Quality BHVN
Gross Margin N/A 80.0%
Operating Margin 0.0% -42.6%
Net Profit Margin 0.0% -47.8%
Return on Equity (ROE) -799.5% -9.9%
4. Balance Sheet & Cash Flow MESO
Cash Generation (TTM) -$473M -$45M EBITDA
Cash Flow Margin N/A -37.1% EBITDA Mgn
Net Cash / Leverage $205M Net Debt $4.38 Book/Sh · -9.9% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning BHVN
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 91.5% (18th %ile) 76.8% (37th %ile)
Put/Call OI Skew 0.31x (Call-Skewed) Thin ADR Chain
OBV Trend / Tech Phase NEUTRAL · Distribution NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: BHVN (5) vs MESO (3)
Institutional Metric BHVN MESO Criterion Row Edge
Market Capitalization
Scale
$2.1B $1.7B Larger Scale BHVN
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% +390.7% Higher Growth MESO
Operating Margin (TTM)
Profitability
0.0% -42.6% Higher Margin BHVN
Net Profit Margin
Profitability
0.0% -47.8% Higher Margin BHVN
Return on Equity (ROE)
Capital Efficiency
-799.5% -9.9% Higher ROE MESO
52-Week Range Position
Momentum
59% ($8–$18) 6% ($12–$22) Stronger Trend BHVN
Beta / 30D Volatility
Risk Regime
1.41β · 111% Vol 1.18β · 78% Vol Lower Realized Risk MESO
Unified Institutional Score
Composite Signal
42.1 / 100 (HOLD) 35.5 / 100 (SELL) Higher Composite BHVN
Trailing 12M Revenue (USD)
Operating Scale
N/A $120M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 80.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 14.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$473M ($205M Net Debt) -$45M EBITDA ($4.38 Book/Sh · -9.9% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon BHVN +35.09 pp
BHVN: +28.99% · MESO: -6.1%
3M Horizon BHVN +27.66 pp
BHVN: +2.47% · MESO: -25.19%
6M Horizon BHVN +78.6 pp
BHVN: +63.78% · MESO: -14.82%
1Y Horizon BHVN +88.51 pp
BHVN: +72.09% · MESO: -16.42%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BHVN vs MESO. Trailing 12-month operating profitability (BHVN 0.0% vs MESO -42.6%) and valuation multiples (BHVN N/M vs MESO N/M Forward P/E) are benchmarked directly in Pillar 4 below.

BHVN ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-799.5% · N/M
MESO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$120M
Gross Margin80.0%
Op. Margin-42.6%
ROE / Fwd P/E-9.9% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
BHVN CONSOLIDATION
91d in phase · OBV NEUTRAL
Current IV 91.5%
IV Percentile 18th %ile
Put/Call OI Skew 0.31x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact BHVN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
MESO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 76.8%
IV Percentile 37th %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact MESO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
BHVN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.1B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
MESO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.7B market capitalization and -42.6% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ BHVN vs MESO Key Questions & Quantitative Answers

As of Nov 16, 2026, Biohaven Ltd. (BHVN) captures the overall head-to-head institutional edge over Mesoblast Limited (MESO) on higher Unified Composite conviction (42.1/100 HOLD vs. 35.5/100 SELL) after splitting the core matrix 5–3 (led by Profitability & Quality, Options & Positioning), while MESO wins 3–2 across the 6-pillar growth and valuation breakdown. BHVN trades at $13.90 (N/M Forward P/E, 0.0% operating margin) versus MESO at $12.47 (N/M Forward P/E, -42.6% operating margin). Growth vs. Quality Trade-Off: BHVN earns the overall head-to-head edge with a stronger Unified Composite Score (42.1/100 HOLD vs. MESO 35.5/100 SELL) and 1.41β · 111% Vol risk profile, whereas MESO leads top-line expansion (+390.7% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: BHVN is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 48.4); meanwhile MESO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 38.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

MESO leads the Growth & Scale pillar: BHVN posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with MESO at +390.7% YoY revenue growth and +0.0% YoY earnings growth on $120M TTM revenue (80.0% gross margin, -42.6% operating margin). On trailing 12-month operating scale, BHVN generates N/A in USD-normalized revenue versus $120M for MESO. In operating R&D and SG&A reinvestment, BHVN deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for MESO.

MESO screens cheaper on headline valuation multiples. BHVN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas MESO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 14.1x EV/Revenue (-37.1% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BHVN (-799.5% ROE) versus MESO (-9.9% ROE) capital efficiency.

In options market volatility and institutional positioning, BHVN carries 91.5% implied volatility (18th %ile, Compressed (<25th %ile)), a 0.31x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.41β · 111% Vol realized risk). By comparison, MESO carries 76.8% implied volatility (37th %ile, Balanced (25th–60th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.18β · 78% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.